US2005271633A1PendingUtilityA1

Issue defect augmentation and repair with in vitro cultured fibroblasts

50
Individually held — no corporate assignee on recordPriority: Feb 20, 1997Filed: Jul 6, 2005Published: Dec 8, 2005
Est. expiryFeb 20, 2017(expired)· nominal 20-yr term from priority
Inventors:Don Kleinsek
C12N 5/0068A61L 27/3895A61K 35/12A61L 27/3683C12N 5/0653A61K 38/00A61L 27/3641C12N 5/0656A61P 11/04A61L 27/24A61L 27/3804A61L 27/3633C12N 2533/54A61L 27/3839
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Certain embodiments herein are directed to a method of treating a tissue associated with a defect in a human including wrinkles, rhytids, depressed scar, cutaneous depressions, stretch marks, hyperplasia of the lip, nasolabial fold, melolabial fold, scarring from acne vulgaris, and post-rhinoplasty irregularity. The tissue defect may be treated by introducing a plurality of in vitro cultured autologous fibroblast cells at or proximal to the defect area of the patient's tissue. The autologous fibroblast cells may have been cultured in vitro to expand the number of fibroblast cells in at least one medium that comprises autologous serum. The autologous fibroblast cell cultures may be derived from connective tissue, dermal, fascial fibroblasts, papillary fibroblasts, and/or reticular fibroblasts.

Claims

exact text as granted — not AI-modified
1 . A method of treating a tissue associated with a defect in a human patient using autologous materials derived from the patient, the method comprising: introducing a plurality of autologous fibroblast cells to the tissue at, or proximal to, the defect of the patient after the plurality of autologous fibroblast cells have been cultured in vitro to expand the number of fibroblast cells in at least one medium that comprises autologous serum, wherein the tissue is associated with a defect chosen from the group consisting of wrinkles, rhytids, depressed scar, cutaneous depressions, stretch marks, hyperplasia of the lip, nasolabial fold, melolabial fold, scarring from acne vulgaris, and post-rhinoplasty irregularity.  
   
   
       2 . The method of  claim 1  wherein extracellular matrix produced in vitro by the autologous fibroblast cells is introduced into the patient in association with the plurality of autologous fibroblast cells.  
   
   
       3 . The method of  claim 1  wherein the autologous fibroblast cells are from connective tissue.  
   
   
       4 . The method of  claim 1  wherein the autologous fibroblast cells comprise lamina propria fibroblasts.  
   
   
       5 . The method of  claim 1  wherein the autologous fibroblast cells comprise fascia fibroblasts.  
   
   
       6 . The method of  claim 1  wherein the autologous fibroblast cells comprise papillary fibroblasts.  
   
   
       7 . The method of  claim 1  wherein the autologous fibroblast cells comprise reticular fibroblasts.  
   
   
       8 . The method of  claim 1  wherein extracellular matrix is introduced into the patient in association with the plurality of autologous fibroblast cells.  
   
   
       9 . The method of  claim 1  wherein collagen or modified collagen is introduced into the patient in association with the plurality of autologous fibroblast cells.  
   
   
       10 . The method of  claim 1  wherein fibronectin is introduced into the patient in association with the plurality of autologous fibroblast cells.  
   
   
       11 . The method of  claim 1  wherein hyaluronic acid is introduced into the patient in association with the plurality of autologous fibroblast cells.  
   
   
       12 . The method of  claim 1  wherein the tissue comprises a member chosen from the group consisting of lower dermis, middle dermis, upper dermis, and skin subcutaneous region.  
   
   
       13 . The method of  claim 1  wherein the issue comprises muscle tissue.

Join the waitlist — get patent alerts

Track US2005271633A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.